Bronwyn Mixter

Currently with @FDAOncology. Formerly with @Clarivate and @BloombergLaw. Mom of 2 kids and a border collie mix. Opinions are my own.

[FDA Oncology @FDAOncology]

Tomorrow! Join #FDAOncology for Conversations on Cancer:
Patients First = Project Facilitate
Project Facilitate helps patients and physicians navigate the Expanded Access pathway to investigational cancer therapies.
June 10th | 12:00 pm ET |Virtual event
https://t.co/a4YpOQAEwU

[FDA Oncology @FDAOncology]

Project Facilitate streamlines access to investigational therapies for patients facing life-threatening cancers.
Join the #FDAOncology Conversations on Cancer discussion:
Patient First = Project Facilitate.
📅 June 10, 2026 | 12:00 pm ET |💻 Virtual event
https://t.co/a4YpOQA6Hm

[FDA Oncology @FDAOncology]

It takes 10-12 years to bring a new drug to patients. One way FDA is working to change that - a new draft guidance on nonclinical safety studies of cancer drugs reduces animal testing, cutting development time while maintaining rigorous safety standards. https://t.co/3Jmmcvqtcv

[FDA Oncology @FDAOncology]

#FDA approves a treatment for high-risk non-muscle invasive bladder cancer. https://t.co/KHPP0Drkg0

[FDA Oncology @FDAOncology]

#FDA approves a treatment for blastic plasmacytoid dendritic cell neoplasm. https://t.co/bsziiUItoP

[FDA Oncology @FDAOncology]

#FDA approves a treatment for unresectable or metastatic triple-negative breast cancer. https://t.co/Pn8CY9cjo3

[FDA Oncology @FDAOncology]

📢 FDA FUNDING: Research cooperative agreement to support new approaches for therapeutic development in ultra-rare cancers.

📅 Apply by June 15, 2026
https://t.co/DItMWQNys2
#UltraRareCancer #FDAFunding

[FDA Oncology @FDAOncology]

#FDA approves a treatment for HER2-positive early-stage breast cancer.

https://t.co/beG6UBMqBz

[FDA Oncology @FDAOncology]

#FDA approves an adjuvant treatment for muscle invasive bladder cancer. https://t.co/ekoIj3b0WU

[FDA Oncology @FDAOncology]

#FDA approves a treatment for acute myeloid leukemia. https://t.co/JvB8z8wqgX

[FDA Oncology @FDAOncology]

#FDA grants accelerated approval to a treatment for relapsed or refractory mantle cell lymphoma. https://t.co/kiTjI1eJjN

[FDA Oncology @FDAOncology]

#FDA grants seventh approval under the National Priority Voucher pilot program.

[FDA Oncology @FDAOncology]

Upcoming Workshop: Contemporary Issues in Non-Muscle Invasive Bladder Cancer (NMIBC) Trial Design & Interpretation

Join the FDA Oncology Center of Excellence for a workshop exploring key challenges and advances in NMIBC research.
https://t.co/nI2jsXfU1E

#NMIBC #BladderCancer

[FDA Oncology @FDAOncology]

#FDA approves a treatment for advanced or metastatic breast cancer. https://t.co/XwpBxNSpXP

[FDA Oncology @FDAOncology]

Clinical trials depend on the expertise of oncology nurses.
Join #FDAOncology for Conversations on Cancer:
“Oncology Nurses – Frontliners in Oncology.”
📅 May 6, 2026 | 💻 Virtual event
https://t.co/a4YpOQA6Hm

#FDAOncology #ConversationsonCancer

[FDA Oncology @FDAOncology]

Nurses play a critical role in oncology drug development.

Join the #FDAOncology Conversations on Cancerdiscussion:

“Oncology Nurses – Frontliners in Oncology.”
📅May 6, 2026 | 💻 Virtual event
https://t.co/UuJho4Nney

[FDA Oncology @FDAOncology]

#FDA approves a treatment for classical Hodgkin lymphoma.

https://t.co/HXzZR7PTRq.

[FDA Oncology @FDAOncology]

#FDA approves a treatment for relapsed or refractory multiple myeloma under the FDA Commissioner’s National Priority Review Voucher (CNPV) pilot program.

https://t.co/qxIFzhiFuW

[FDA Oncology @FDAOncology]

Today, the FDA issued approval for a lung cancer drug as part of the new Commissioner's National Priority Voucher (CNPV) pilot program. https://t.co/74LO4JErnZ

[FDA Oncology @FDAOncology]

FDA grants traditional approval to a treatment for metastatic colorectal cancer with a BRAF V600E mutation. https://t.co/d2NERaNqS8